Anti CD123 chimeric antigen receptor T-cell therapy (Nanjing Legend Biotech)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameAnti CD123 chimeric antigen receptor T-cell therapy (Nanjing Legend Biotech)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsLeukemia, Myeloid, AcuteLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaDiscontinued

Originator CompaniesNanjingjinsirui Science & Technology Biology Corp

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNanjing Legend Biotechnology Co Ltd

Active IndicationsN/A

Inactive IndicationsLeukemia, Myeloid, AcuteLeukemia

Other Information

ATC CodeN/A